Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
164M
-
Shares change
-
-1.78M
-
Total reported value, excl. options
-
$460M
-
Value change
-
-$1.96M
-
Put/Call ratio
-
1.91
-
Number of buys
-
65
-
Number of sells
-
-73
-
Price
-
$2.80
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2024
184 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2024.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 164M shares
of 226M outstanding shares and own 72.66% of the company stock.
Largest 10 shareholders include FMR LLC (30M shares), TPG GP A, LLC (18.7M shares), BlackRock, Inc. (17.8M shares), VANGUARD GROUP INC (8.33M shares), STATE STREET CORP (7.01M shares), Capital World Investors (6.9M shares), Lynx1 Capital Management LP (6.2M shares), PRIMECAP MANAGEMENT CO/CA/ (5.67M shares), CITADEL ADVISORS LLC (5.04M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (4.84M shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.